文献速递肝病

Th17细胞频率与原发性硬化性胆管炎低骨量相关

Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.
PubMed 文献 · J Hepatol · 2019-01-11

研究通过双X线吸收法和高分辨率外周定量CT评估原发性硬化性胆管炎(PSC)患者骨密度与微结构,发现骨丢失与病程及肝纤维化无关,但骨吸收标志物脱氧吡啶啉与骨密度负相关,外周血Th17细胞频率与尿脱氧吡啶啉正相关、与骨量负相关;Abcb4缺陷小鼠低骨量表型可被Il-17缺陷或抗IL-17治疗纠正,而肝脏病理未受影响。

要点

  • PSC患者骨丢失与疾病病程和肝纤维化无关,但与骨吸收增加相关。
  • 外周血Th17细胞频率与尿脱氧吡啶啉正相关、与骨量负相关。
  • Abcb4缺陷小鼠低骨量表型可被Il-17缺陷或抗IL-17治疗纠正,肝脏病理未受影响。

核心结论

  • 研究结果表明,Th17细胞频率增加与PSC中的骨吸收相关。
  • 基于抗体的IL-17阻断是否对PSC患者骨丢失有益,应在未来研究中解决。

研究设计与样本

  • 对PSC患者采用双X线吸收法测定骨密度,并采用高分辨率外周定量计算机断层扫描评估骨微结构。
  • 检测肝脏和骨代谢的实验室标志物,并通过FibroScan评估肝硬度。
  • 在40例PSC患者亚组中,通过离体刺激外周血单核细胞确定Th17细胞频率。
  • 分析缺乏Abcb4和/或Il-17的小鼠的骨骼表型,以探究IL-17在PSC相关骨丢失中的潜在参与。

主要发现

  • 与原发性胆汁性胆管炎患者不同,PSC患者的骨丢失与疾病病程或肝纤维化无关。
  • 在PSC队列中观察到骨吸收生物标志物脱氧吡啶啉与骨密度之间呈显著负相关,表明骨吸收增加。
  • 外周血Th17细胞频率与尿脱氧吡啶啉水平呈正相关,与骨量呈负相关。
  • Abcb4缺陷小鼠表现出低骨量表型,额外Il-17缺陷或抗IL-17治疗可纠正该表型,而肝脏病理未受影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Osteoporotic fractures are a major cause of morbidity and reduced quality of life in patients with primary sclerosing cholangitis (PSC), a progressive bile duct disease of unknown origin. Although it is generally assumed that this pathology is a consequence of impaired calcium homeostasis and malabsorption, the cellular and molecular causes of PSC-associated osteoporosis are unknown. METHODS: We determined bone mineral density by dual-X-ray absorptiometry and assessed bone microstructure by high-resolution peripheral quantitative computed tomography in patients with PSC. Laboratory markers of liver and bone metabolism were measured, and liver stiffness was assessed by FibroScan. We determined the frequency of Th17 cells by the ex vivo stimulation of peripheral blood mononuclear cells in a subgroup of 40 patients with PSC. To investigate the potential involvement of IL-17 in PSC-associated bone loss, we analyzed the skeletal phenotype of mice lacking Abcb4 and/or Il-17. RESULTS: Unlike in patients with primary biliary cholangitis, bone loss in patients with PSC was not associated with disease duration or liver fibrosis. However, we observed a significant negative correlation between the bone resorption biomarker deoxypyridinoline and bone mineral density in the PSC cohort, indicating increased bone resorption. Importantly, the frequency of Th17 cells in peripheral blood was positively correlated with the urinary deoxypyridinoline level and negatively correlated with bone mass. We observed that Abcb4-deficient mice displayed a low-bone-mass phenotype, which was corrected by an additional Il-17 deficiency or anti-IL-17 treatment, whereas the liver pathology was unaffected. CONCLUSIONS: Our findings demonstrate that an increased frequency of Th17 cells is associated with bone resorption in PSC. Whether antibody-based IL-17 blockade is beneficial against bone loss in patients with PSC should be addressed in future studies. LAY SUMMARY: Primary sclerosing cholangitis (PSC) is a cholestatic liver disease characterized by progressive bile duct destruction. One serious complication of PSC is reduced bone mass resulting in increased fracture risk. Herein, we demonstrate that Th17 cells mediate bone loss in PSC by inducing bone resorption, which suggests that antibody-based IL-17 blockade might be beneficial for the treatment of bone loss in affected patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Schmidt T, Schwinge D, Rolvien T, et al. Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. J Hepatol. 2019. PMID: 30641095. doi:10.1016/j.jhep.2018.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。